4. INCREMENTO DE MORTALIDAD ASOCIADA A FA
p<0,0001
55-74 años
Benjamin, et al. Impact of Atrial Fibrillation on the Risk of Death : The Framingham Heart Study. Circulation 1998
75-94 años
5. From: Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial
Fibrillation
Ann Intern Med. 2007;146(12):857-867.
64%
ACV
26%
Mortalidad
4.713
pacientes
6. (a) Factores de riesgo de ictus y tromboembolismo en la FA no valvular
Factores de riesgo mayores
Factores de riesgo menos validados o con menos
poder
Antecedentes de ictus, AIT o embolismo sistémico
Edad ≥ 75 años
Insuficiencia cardíaca o disfunción sistólica del
ventrículo izquierdo de moderada a severa (p. ej. FE VI
≤ 40%)
Hipertensión-diabetes mellitus
Sexo femenino-edad: 657-74 años
Enfermedad vasculara
(b) Escala de riesgo de ictus en FA: CHa2DS2-VASc [Congestive heart failure, Hypertension, Age ≥ 75 (2 =
doubled), Diabetes Stroke (2 = doubled), Vascular disease, Age 65-74, Sex Category (female)]
(Nota: la máxima puntuación es 9, ya que la edad puede aportar 0, 1 o 2 puntos)
Factor de riesgo Puntuación
Insuficiencia cardíaca congestiva/disfunción VI 1
Hipertensión 1
Edad ≥ 75 años 2
Diabetes mellitus 1
Ictus/AIT/tromboembolismo 2
Enfermedad vasculara 1
Edad: 65-74 años 1
Sexo femenino 1
Puntuación máxima 9
Lip GY, et al. Stroke. 2010;41:2731-8.
Camm AJ, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of AF of the ESC. Eur Heart J 2010;doi:10.1093/eurheartj/ehq278.
1.30%
2.20%
3.20%
4.00%
6.70%
9.80% 9.60%
6.70%
15.20%
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
12.00%
14.00%
16.00%
1 2 3 4 5 6 7 8 9
EVALUACIÓN DE RIESGO ICTUS
7. ANTICOAGULAMOS A LA MITAD DE PACIENTES
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
GWTG-HF Medicare NRAF II UHSC ATRIA NSTEMI STEMI
65.0%
46.0%
65.0%
44.0%
55.0%
31.0%
39.0%
GWTG-HF: Get With the Guidelines – Heart Failure. NRAF II: National Registry of Atrial Fibrillation, UHSC: University
Healthsystem Consortium, ATRIA: Anticoagulación and Risk Factor in Atrial Fibrillation Registry, NSTEMI: Patients with
non-ST segment elevation myocaridal infarction, STEMI: Patients with ST-segment elevation myocardia infarction
Relative effects of antithrombotic therapies on all stroke from randomized trials in patients with atrial fibrillation.Horizontal lines represent 95% CIs around point estimates. Please see footnote in Table 1 for definitions of study acronyms. A. Adjusted-dose warfarin compared with placebo or no treatment in 6 randomized trials. B. Antiplatelet agents compared with placebo or no treatment in 8 randomized trials. In SAFT (23), aspirin was combined with low, inefficacious dosages of warfarin. In ESPS II (13), combination refers to aspirin plus dipyridamole. C. Adjusted-dose warfarin compared with antiplatelet agents in 11 randomized trials. Nonaspirin antiplatelet agents were indobufen (SIFA [12]), clopidogrel plus aspirin (ACTIVE-W [28]), and triflusal (NASPEAF [25]). *The Vemmos et al. (27) and WASPO (31) trials are not shown; however, the information is shown in Table 4.